Health tech startup Cadence secured a $100 million series C funding round to scale artificial intelligence agents for chronic disease management.
Spark Capital led the funding round, with participation from Thrive Capital, General Catalyst, Coatue, B Capital, Corewell Health Ventures, Memorial Hermann and Duke Health. The company plans to use the fresh funding to advance its AI agents, grow in value-based care models and expand across new health systems.
The company raise a $100 million series B round in December 2021.
Spark Capital Partner and Cadence board member Will Reed said in a statement the “most consequential AI companies of the next decade” will be those built for areas where “technology changes the underlying mechanics of the business.”
“Cadence has done the hardest work first - demonstrating clinical outcomes, building trust with the country's leading health systems, and proving out the safe and effective deployment of AI inside care delivery,” said Reed. “There is no other AI care platform in the country with this combination of scale, peer-reviewed clinical outcomes, and economic proof.”
The company’s Clinical Intelligence platform identifies risk early and supports older patients in between visits through daily vital monitoring, timely medication adjustment support and personalized lifestyle coaching. It’s embedded directly into partner health systems’ medical groups, electronic medical records (EMRs) and clinical workflows. Supervised AI agents monitor patient vitals daily, support timely medication adjustments and enable highly personalized lifestyle coaching.
Cadence Founder and CEO Chris Altcheck said in a statement the platform was built to “solve the clinical labor constraint at the heart of the chronic disease crisis.”
“Our AI automates care under close supervision, guided by our medical group, governed by our health system clinical protocols, and reimbursed through billing infrastructure and at-risk contracts," said Altcheck. “We're treating 100,000 patients with that system today, alongside partners committed to changing the status quo in chronic care. This investment builds the infrastructure to treat millions.”
Cadence works with more than 20 health systems and treats more than 100,000 active patients. The company tripled annual recurring revenue in 2025 and saves Medicare roughly $2.7 million weekly, executives say.
Alongside the funding, Cadence announced new affiliations with Duke Health and Texas Health Resources.
"At Duke Health, our mission is to advance the health of our patients and the communities we serve. The moments that matter most for a patient's health often happen at home, not in the clinic," said Jeffrey Ferranti, M.D., senior vice president and chief digital officer of Duke Health, in a statement. "With Cadence, we stay connected to patients with chronic conditions around the clock, monitoring their health continuously so we can intervene early and keep them healthy. Together, we're reimagining what care can be: healthier patients and a stronger, more affordable health system for all."
The company points to peer-reviewed studies demonstrating that its model has produced validated outcomes. One Mayo Clinic study found that Cadence's model drove a 27% reduction in hospital admissions and $1,302 per-patient annual reduction in total cost of care. A study published in the Journal of the American College of Cardiology found that Cadence's remote patient care hypertension program led to a 70% improvement in blood pressure control for hypertension patients.